Pulse Biosciences (PLSE) Net Income towards Common Stockholders (2020 - 2025)
Pulse Biosciences has reported Net Income towards Common Stockholders over the past 6 years, most recently at -$19.4 million for Q3 2025.
- Quarterly results put Net Income towards Common Stockholders at -$19.4 million for Q3 2025, down 52.73% from a year ago — trailing twelve months through Dec 2025 was -$55.3 million (down 203.23% YoY), and the annual figure for FY2025 was $72.8 million, up 35.82%.
- Net Income towards Common Stockholders for Q3 2025 was -$19.4 million at Pulse Biosciences, down from -$19.2 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for PLSE hit a ceiling of $87.8 million in Q4 2024 and a floor of -$19.4 million in Q3 2025.
- Median Net Income towards Common Stockholders over the past 5 years was -$14.0 million (2022), compared with a mean of -$6.6 million.
- Biggest five-year swings in Net Income towards Common Stockholders: soared 429.21% in 2023 and later tumbled 68.39% in 2025.
- Pulse Biosciences' Net Income towards Common Stockholders stood at -$15.4 million in 2021, then soared by 40.34% to -$9.2 million in 2022, then soared by 429.21% to $30.3 million in 2023, then skyrocketed by 189.99% to $87.8 million in 2024, then crashed by 122.06% to -$19.4 million in 2025.
- The last three reported values for Net Income towards Common Stockholders were -$19.4 million (Q3 2025), -$19.2 million (Q2 2025), and -$16.8 million (Q1 2025) per Business Quant data.